Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03185897 · ClinicalTrials.gov registry record
Global Epidemiologic Study of Preexisting Immunity to AAV in Adults With Severe Hemophilia
A clinical trial, sponsored by Baxalta now part of Shire.
- Completed
- Registry status
- 242
- Enrollment target
NCT03185897 is a clinical trial that has completed, run by Baxalta now part of Shire. The registered enrollment target is 242 participants.
The verdict
NCT03185897 has completed, sponsored by Baxalta now part of Shire.
- COMPLETED
- Registry status
- 242 participants
- Enrollment target
Study Summary
Assess the seroprevalence of neutralizing antibodies (NAb) to AAV in adults with severe hemophilia A (coagulation factor VIII \[FVIII\] \<1%) or moderately severe to severe hemophilia B (coagulation factor IX \[FIX\] ≤2%).
Interventions
- OTHER Non-treatment, seroprevalence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2017-06-14 |
| Est. Completion | 2021-03-17 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03185897
The ClinicalTrials.gov registry entry for NCT03185897 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 242 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baxalta now part of Shire, which has 74 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Non-treatment, seroprevalence is the first listed.
NCT03185897 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03185897 about?
NCT03185897 is a clinical study titled "Global Epidemiologic Study of Preexisting Immunity to AAV in Adults With Severe Hemophilia". Assess the seroprevalence of neutralizing antibodies (NAb) to AAV in adults with severe hemophilia A (coagulation factor VIII \[FVIII\] \<1%) or moderately severe to severe hemophilia B (coagulation factor IX \[FIX\] ≤2%).
What is the current status of trial NCT03185897?
This trial is currently completed. The enrollment target is 242 participants. The study started on 2017-06-14. Estimated completion is 2021-03-17.
What interventions are being tested in trial NCT03185897?
The interventions under investigation include: Non-treatment, seroprevalence (OTHER).
Who is sponsoring clinical trial NCT03185897?
This trial is sponsored by Baxalta now part of Shire, which has 74 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.